Home > Journals > Minerva Gastroenterology > Past Issues > Minerva Gastroenterology 2022 September;68(3) > Minerva Gastroenterology 2022 September;68(3):346-7

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

LETTERS TO THE EDITOR   Free accessfree

Minerva Gastroenterology 2022 September;68(3):346-7

DOI: 10.23736/S2724-5985.21.02921-1

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Safety of bevacizumab combined with chemotherapy in the treatment of recurrent ovarian cancer and its effect on adverse reactions and digestive function

Ping JIA 1, Suwen CHANG 2, Yanan ZHANG 3, Ruifang TANG 4, Xing LIU 5, Yingjia XU 6, Aimin LIANG 7

1 Department of Obstetrics and Gynecology, Xiangyang N.1 People’s Hospital Affiliated Hospital of Hubei University of Medicine, Xiangyang, China; 2 Department of Gynecology, Yantai Yuhuangding Hospital, Yantai, China; 3 Department of Nursing, People’s Hospital of Xiangzhou District, Xiangyang, China; 4 Dongfeng Emergency Station, Xiangyang Emergency Center, Xiangyang, China; 5 Department of Neurosurgery, Xiangyang N.1 People’s Hospital Affiliated Hospital of Hubei University of Medicine, Xiangyang, China; 6 Department of Nursing, Institute of Medicine and Nursing, Hubei University of Medicine, Shiyan, China; 7 UCC, Xiangyang N.1 People’s Affiliated Hospital of Hubei University of Medicine, Xiangyang, China



top of page